Precision IBD Rebrands as Prometheus and Strikes R&D Deal With Takeda

This summer Nestl? Health Science sold Prometheus Laboratories, a gastrointestinal disease diagnostics unit it had acquired eight years prior, to a low-profile San Diego biotech called Precision IBD. About a month ago, Precision?a drug and diagnostic developer that?s focused, as its name suggests, on inflammatory bowel disease (IBD)?changed its name to Prometheus Biosciences and tapped [?]